Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation

Oncotarget

Volumn 7, Issue 13, 2016, Pages 16593-16609

  Chen, Weiqian ^a,b   Zou, Peng ^a,c   Zhao, Zhongwei ^b   Weng, Qiaoyou ^b   Chen, Xi ^a   Ying, Shilong ^a   Ye, Qingqing ^a   Wang, Zhe ^a   Ji, Jiansong ^b   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

^c NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ER stress; Gastric cancer; Mitochondrial dysfunction; Reactive oxygen species (ROS); Thioredoxin reductase 1

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CURCUMIN DERIVATIVE B19; CYSTEINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG; CURCUMIN; TXNRD1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CATALYSIS; CELL CYCLE ARREST; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; COVALENT BOND; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; OXIDATIVE STRESS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT DURATION; TUMOR VOLUME; TUMOR WEIGHT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR LIBRARY; NUDE MOUSE; PHARMACOLOGY; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CURCUMIN; ENDOPLASMIC RETICULUM STRESS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SMALL MOLECULE LIBRARIES; STOMACH NEOPLASMS; THIOREDOXIN REDUCTASE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971667709     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7565     Document Type: Article

References (40)

1. Powis G, Gasdaska JR, Gasdaska PY, Berggren M, Kirkpatrick DL, Engman L, Cotgreave IA, Angulo M and Baker A. Selenium and the thioredoxin redox system: effects on cell growth and death. Oncology research. 1997; 9:303-312.
2. Sun Y and Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer research. 2008; 68:8269-8277.
3. Yin F, Sancheti H and Cadenas E. Mitochondrial thiols in the regulation of cell death pathways. Antioxidants & redox signaling. 2012; 17:1714-1727.
4. Singh I. Mammalian peroxisomes: metabolism of oxygen and reactive oxygen species. Annals of the New York Academy of Sciences. 1996; 804:612-627.
5. Cairns RA, Harris IS and Mak TW. Regulation of cancer cell metabolism. Nature reviews Cancer. 2011; 11:85-95.
6. Trachootham D, Alexandre J and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature reviews Drug discovery. 2009; 8:579-591.
7. Simon HU, Haj-Yehia A and Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis : an international journal on programmed cell death. 2000; 5:415-418.
8. Patenaude A, Ven Murthy MR and Mirault ME. Mitochondrial thioredoxin system: effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. The Journal of biological chemistry. 2004; 279:27302-27314.
9. Zhao F, Yan J, Deng SJ, Lan LX, He F, Kuang B and Zeng HH. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines. Cancer Lett. 2006; 236:46-53.
10. Lan L, Zhao F, Wang Y and Zeng H. The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: possible involvement of nuclear factor-kappaB-dependent pathway. European journal of pharmacology. 2007; 555:83-92.
11. Yan C, Siegel D, Newsome J, Chilloux A, Moody CJ and Ross D. Antitumor indolequinones induced apoptosis in human pancreatic cancer cells via inhibition of thioredoxin reductase and activation of redox signaling. Molecular pharmacology. 2012; 81:401-410.
12. Das KC and Das CK. Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochemical and biophysical research communications. 2000; 277:443-447.
13. Bjornstedt M, Hamberg M, Kumar S, Xue J and Holmgren A. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. The Journal of biological chemistry. 1995; 270:11761-11764.
14. Xia L, Nordman T, Olsson JM, Damdimopoulos A, Bjorkhem-Bergman L, Nalvarte I, Eriksson LC, Arner ES, Spyrou G and Bjornstedt M. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. The Journal of biological chemistry. 2003; 278:2141-2146.
15. Rigobello MP and Bindoli A. Mitochondrial thioredoxin reductase purification, inhibitor studies, and role in cell signaling. Methods in enzymology. 2010; 474:109-122.
16. Biaglow JE and Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer biology & therapy. 2005; 4:6-13.
17. Cai W, Zhang L, Song Y, Wang B, Zhang B, Cui X, Hu G, Liu Y, Wu J and Fang J. Small molecule inhibitors of mammalian thioredoxin reductase. Free radical biology & medicine. 2012; 52:257-265.
18. Thannickal VJ and Fanburg BL. Reactive oxygen species in cell signaling. American journal of physiology Lung cellular and molecular physiology. 2000; 279:L1005-1028.
19. Sachweh MC, Stafford WC, Drummond CJ, McCarthy AR, Higgins M, Campbell J, Brodin B, Arner ES and Lain S. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget. 2015; 6:16488-16506. doi: 10.18632/oncotarget.4108.
20. Wang Y, Xiao J, Zhou H, Yang S, Wu X, Jiang C, Zhao Y, Liang D, Li X and Liang G. A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis (2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancercell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. Journal of medicinal chemistry. 2011; 54:3768-3778.
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917.
22. Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D and Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013; 49:3616-3624.
23. Cai W, Zhang B, Duan D, Wu J and Fang J. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicology and applied pharmacology. 2012; 262:341-348.
24. Cenas N, Nivinskas H, Anusevicius Z, Sarlauskas J, Lederer F and Arner ES. Interactions of quinones with thioredoxin reductase: a challenge to the antioxidant role of the mammalian selenoprotein. The Journal of biological chemistry. 2004; 279:2583-2592.
25. Kunkel MW, Kirkpatrick DL, Johnson JI and Powis G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. Anti-cancer drug design. 1997; 12:659-670.
26. Xu J and Arner ES. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase. Biochem Pharmacol. 2012; 83:815-820.
27. Mau BL and Powis G. Inhibition of thioredoxin reductase (E.C. 1.6.4.5.) by antitumor quinones. Free radical research communications. 1990; 8:365-372.
28. Jan YH, Heck DE, Dragomir AC, Gardner CR, Laskin DL and Laskin JD. Acetaminophen reactive intermediates target hepatic thioredoxin reductase. Chemical research in toxicology. 2014; 27:882-894.
29. Duan D, Zhang B, Yao J, Liu Y and Fang J. Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells. Free radical biology & medicine. 2014; 70:182-193.
30. An D, Su J, Weber JK, Gao X, Zhou R and Li J. A Peptide-Coated Gold Nanocluster Exhibits Unique Behavior in Protein Activity Inhibition. Journal of the American Chemical Society. 2015; 137:8412-8418.
31. Qu W, Xiao J, Zhang H, Chen Q, Wang Z, Shi H, Gong L, Chen J, Liu Y, Cao R and Lv J. B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. International journal of biological sciences. 2013; 9:766-777.
32. Moserova I and Kralova J. Role of ER stress response in photodynamic therapy: ROS generated in different subcellular compartments trigger diverse cell death pathways. PloS one. 2012; 7:e32972.
33. Vrablic AS, Albright CD, Craciunescu CN, Salganik RI and Zeisel SH. Altered mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. FASEB. 2001; 15:1739-1744.
34. Moon DO, Park SY, Choi YH, Ahn JS and Kim GY. Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: Involvement of ROS-dependent ER-stress. Biochem Pharmacol. 2011; 82:1641-1650.
35. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP, Piette J, Linehan C, Gupta S, Samali A and Agostinis P. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell death and differentiation. 2012; 19:1880-1891.
36. Zou P, Chen M, Ji J, Chen W, Chen X, Ying S, Zhang J, Zhang Z, Liu Z, Yang S and Liang G. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer. Oncotarget. 2015; 6:36505-36521. doi: 10.18632/oncotarget.5364.
37. Holmgren A and Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochemical and biophysical research communications. 2010; 396:120-124.
38. Kondo N, Nakamura H, Masutani H and Yodoi J. Redox regulation of human thioredoxin network. Antioxidants & redox signaling. 2006; 8:1881-1890.
39. Nordberg J and Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free radical biology & medicine. 2001; 31:1287-1312.
40. Nguyen P, Awwad RT, Smart DDK, Spitz DR and Gius D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2006; 236:164-174.